Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675117 | 0.84 | KIF11 (0.51) | KIF11KDM4EALDH1A1POLBMAPT | |
| SCHEMBL28280007 | 0.82 | ACHE (0.54) | KIF11PDK2PDK4ACHEKDM4E | |
| SCHEMBL3942223 | 0.80 | PDK2 (0.39) | PDK2PDK4ACHEKDM4EMEN1 | |
| SCHEMBL20006729 | 0.79 | KIF11 (0.66) | KIF11ACHEKDM4EMEN1NPC1 | |
| SCHEMBL4421221 | 0.77 | CHUK (0.47) | PDK2PDK4ACHEHPGD | |
| SCHEMBL13598869 | 0.77 | PDK2 (0.43) | PDK2PDK4ACHEKDM4E | |
| SCHEMBL20685571 | 0.77 | CHUK (0.47) | PDK2PDK4ACHEMEN1NPC1 | |
| SCHEMBL20685567 | 0.77 | KIF11 (0.53) | KIF11PDK2PDK4ACHEKDM4E | |
| SCHEMBL678622 | 0.76 | KIF11 (0.61) | KIF11MEN1MAPTKMT2A | |
| SCHEMBL3942220 | 0.75 | KIF11 (0.57) | KIF11PDK2PDK4KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | XDH, F7, CYP4X1 | KIF11 3047/4885PDK2 178/4885PDK4 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.